原发性肝癌脂代谢相关通路及药物干预的研究进展

Research progress on lipid metabolism related pathways of primary hepatic carcinoma and intervention with medicines

原发性肝癌(简称肝癌)是一种常见的消化道肿瘤,起病隐匿,进展迅速,发病率逐年提高。目前,肝癌仍缺乏特异性的早期诊断和治疗标志物,对肝癌生物学特性和发病机制的研究变得十分迫切。代谢重编程是肿瘤细胞的主要特征之一,脂质代谢重编程参与肝癌的发生发展进程。因此,脂代谢过程中的关键代谢酶及调控分子被认为是肝癌诊断与治疗的重要靶点。本文主要围绕肝癌脂代谢有关的信号通路和调控分子以及相关的抗肝癌药物进行综述,从而为肝癌的防治提供新思路。

Primary hepatic carcinoma,hepatic carcinoma for short,is a common gastrointestinal tumor with an insidious onset and rapid progression,and its incidence rate is increasing year by year,seriously threatening the life and health of our people.At present,there is still a lack of specific markers for early diagnosis and treatment of hepatic carcinoma,so the research on its biological characteristics and pathogenesis has become very urgent.Metabolic reprogramming is one of the main characteristics of tumor cells,and lipid metabolic reprogramming is involved in the occurrence and development of hepatic carcinoma.Therefore,the key metabolic enzymes and regulatory molecules in the process of lipid metabolism are considered as important targets for the diagnosis and treatment of hepatic carcinoma.This paper mainly focuses on the signaling pathways and regulatory molecules related to hepatocellular carcinoma lipid metabolism,as well as the related anti-hepatoma drugs,so as to provide new ideas for the prevention and treatment of hepatic carcinoma.